Safety Notices

From time to time notices relating to the safety and/or quality of medicinal products are published by the Health Products Regulatory Authority

These notices are classified under several priority related categories and may relate to human and veterinary medicines, or medical devices.   

The issues covered by these notices will range from quality defect information and medicinal product safety information through to updated information on the appropriate usage of medicines or devices.

Notices are categorised in accordance with their importance at time of publication.

The four notice categories are outlined as follows:

  • Advisory  -  Routine safety information            
  • Warning  -  Urgent safety information
  • Recall  -  Urgent safety information relating to a product recall
  • Publications  -  General safety information provided by the HPRA for publication via 3rd parties e.g. MIMS

The HPRA Drug Safety Newsletter is also published on a regular basis.

Date Title Type
09/10/2017 HPRA MIMS Article October 2017 - Daclizumab (Zinbryta) and Risk of Severe Liver Injury: Initiation in Multiple Sclerosis Now Restricted, Promptly Review Patients Already on Treatment 3rd Party Publications
02/10/2017 Human Epoetins: Important Safety Information from the Marketing Authorization Holders (MAHs) of all epoetins as approved by the HPRA 3rd Party Publications
02/10/2017 Direct Healthcare Professional Communications (DHPCs) - Issued in September 2017 3rd Party Publications
29/09/2017 Pharmacovigilance Risk Assessment Committee (PRAC) Meeting Highlights 3rd Party Publications
21/09/2017 Humalog (insulin lispro) - Important Safety Information from Eli Lilly and Co (Ireland) Limited as approved by the HPRA (Sept 2017) 3rd Party Publications
08/09/2017 Dacogen (decitabine) - Important Safety Information from Janssen-Cilag Limited as approved by the HPRA 3rd Party Publications
04/09/2017 HPRA MIMS Article September 2017 - Amoxicillin; Co-Amoxiclav – Very Rare Reports of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) 3rd Party Publications
24/08/2017 Methylprednisolone - Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA 3rd Party Publications
23/08/2017 HPRA IMF Article August 2017 - Domperidone-containing medicines: Reminder of the risk of cardiac adverse reactions-restricted indication, contraindications and reduced dose and duration of use 3rd Party Publications
26/07/2017 HPRA MIMS article July/August 2017 - Domperidone-containing medicines: Reminder of the risk of cardiac adverse reactions - restricted indication, contraindications and reduced dose and duration of use 3rd Party Publications